Outpatient Bispecific Administration and Workflow in DLBCL

Dr. Johnson discusses the FDA's April 2026 update to the epcoritamab label permitting outpatient monitoring for the first full 48 mg dose in relapsed/refractory DLBCL. This enables broader geographic access within large clinical networks, allowing community-affiliated sites to administer bispecifics without mandating hospitalization at the tertiary center. His center's necessary infrastructure includes pharmacy teaching sessions, patient wallet cards, next-day nursing phone check-ins, home temperature monitoring, and outpatient cytokine release syndrome management pathways that allow many grade 1 to 2 events to be handled without hospitalization.

Dr. Lunning argues that tarlatamab in small-cell lung cancer has been an unexpected driver of bispecific antibody familiarity in community oncology practices; disease incidence essentially forces non-lymphoma oncologists to learn cytokine release syndrome management. He observes that community practices managing tarlatamab successfully should feel equally capable of managing lymphoma bispecifics, noting that tarlatamab patients almost uniformly experience some cytokine release syndrome, making it arguably a more challenging introductory agent than most lymphoma bispecifics.

Dr. Graff confirms this from her community practice, describing management of over 50 patients with tarlatamab predominantly in outpatient settings through a well-established round-the-clock clinic cytokine release syndrome protocol. She notes that even traditionally hesitant community practices tend to begin with tarlatamab rather than lymphoma or myeloma bispecifics, suggesting that once cytokine release syndrome management is mastered in any disease context, the skills transfer readily.

Dr. Westin concludes that maintaining a posture of "I'll send those patients elsewhere" for bispecifics is increasingly difficult to justify as more indications across tumor types arrive, and that building bispecific competency now will serve practices across the field.